Patent intelligence · US
US 9624233
Compounds for treating pruritic conditions
Compounds for treating pruritic conditions
Patent details — US 9624233
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 18, 2017
- Expiration
- Apr 13, 2037
- Applicant
- Trevi Therapeutics, Inc.
- Claims
- 26
- CPC classes
- A61P, A61P17/04
Quick answer
US 9624233 (Compounds for treating pruritic conditions) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Apr 18, 2017. Expires Apr 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Trevi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61P, A61P17/04
More from Trevi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12274696
Methods of administering nalbuphine
granted -
US 11660296
Treatment of chronic cough, breathlessness and dyspnea
granted -
US 10238646
Methods for treating pruritus
granted -
US 8987289
Methods for treating pruritus
granted -
US 8940753
Methods for treating pruritis
granted -
US 8637538
Methods for treatment of pruritis
granted
Frequently asked questions
What is US patent 9624233?
US 9624233 (Compounds for treating pruritic conditions) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Apr 18, 2017. Expires Apr 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9624233?
Trevi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9624233 expire?
Our index shows an expiration date of Apr 13, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.